source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Business Wire | 2021-05-14 20:48:00 | https://www.businesswire.com/news/home/20210513005800/en/CORRECTING-and-REPLACING-AbCellera-Reports-Q1-2021-Business-Results/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results | CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2021-05-14 11:51:00 | https://www.investors.com/news/technology/abcellera-stock-why-in-line-royalties-for-covid-drug-were-not-enough/ | AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled. | Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-13 21:51:04 | https://seekingalpha.com/article/4428515-abcellera-biologics-inc-abcl-ceo-carl-hansen-on-q1-2021-results-earnings-call-transcript | AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript | AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-05-04 09:31:26 | https://www.benzinga.com/general/biotech/21/05/20934404/abcellera-lilly-partnered-second-covid-19-antibody-enters-human-trials | AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other mon... | AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-04-05 14:00:00 | https://www.businesswire.com/news/home/20210405005386/en/Published-Peer-Reviewed-Data-Demonstrate-Bamlanivimab%E2%80%99s-High-Potency-Against-SARS-CoV-2-and-Support-its-Use-as-a-Foundational-Antibody-Therapy-to-Treat-and-Prevent-COVID-19/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19. | Published Peer-Reviewed Data Demonstrate Bamlanivimab's High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-04-01 10:05:00 | https://www.benzinga.com/general/biotech/21/04/20446372/abcellera-gilead-ink-new-multi-target-antibody-discovery-collaboration | AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration. Under the agreements' financial terms, AbCellera will receive an upfront payment and is eligible for milestone payme... | AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-03-30 06:51:47 | https://pulse2.com/abcl-stock-price-nasdaq-abcellera-biologics-increased-over-10-pre-market-why-it-happened/ | The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by over 10% pre-market. This is why it happened. | ABCL Stock Price Increased Over 10% Pre-Market: Why It Happened | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-29 22:50:07 | https://seekingalpha.com/article/4416694-abcellera-biologics-abcl-ceo-carl-hansen-on-q4-2020-results-earnings-call-transcript | AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript | AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-08 02:29:22 | https://seekingalpha.com/article/4412135-abcellera-biologics-compounding-machine-biotech | AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries. With the likes of Bill Gates, Peter Thiel and DARPA as key backers, AbCellera is quietly creating a call option on vast swaths of new and emerging biotech. | AbCellera Biologics: A Compounding Machine In Biotech Clothing | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-03-05 15:30:00 | https://www.businesswire.com/news/home/20210305005554/en/EMA-Advises-Use-of-AbCellera-Discovered-Bamlanivimab-Alone-or-Together-with-Etesevimab-to-Treat-Confirmed-COVID-19-Patients/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients | EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-02-17 16:05:00 | https://www.businesswire.com/news/home/20210217005913/en/AbCellera-to-Present-at-the-SVB-Leerink-Global-Healthcare-Conference/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time. | AbCellera to Present at the SVB Leerink Global Healthcare Conference | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-02-10 11:47:07 | https://www.benzinga.com/news/21/02/19592601/why-azurrx-biopharma-usana-health-are-moving-today | Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. The company also announced a $150 million buyback. | Why AzurRx BioPharma, Usana Health Are Moving Today | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-02-09 20:26:00 | https://www.businesswire.com/news/home/20210209006299/en/AbCellera-Discovered-Antibody-Bamlanivimab-Administered-with-Etesevimab-Receives-FDA-Emergency-Use-Authorization-for-COVID-19/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #EUA--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 | AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-01-27 07:22:00 | https://www.businesswire.com/news/home/20210127005492/en/AbCellera-Discovered-Antibody-Bamlanivimab-to-be-Developed-with-VIR-7831-for-the-Treatment-of-COVID-19/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 | AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-01-26 07:09:00 | https://www.businesswire.com/news/home/20210126005601/en/AbCellera-Discovered-Antibody-Bamlanivimab-Administered-with-Etesevimab-Reduced-Risk-of-COVID-19-Hospitalizations-and-Death-by-70/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% | AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-01-19 16:41:00 | https://www.businesswire.com/news/home/20210119006096/en/AbCellera-Granted-U.S.-Patent-Covering-its-Trianni-Mouse%C2%AE-Technology/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. | AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-01-13 15:55:38 | https://www.youtube.com/watch?v=mMKOnkANiqk | AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments. | AbCellera CEO on effectiveness of Covid-19 anitbody treatment | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2020-12-22 17:24:46 | https://www.gurufocus.com/news/1317118/andreas-halvorsen-jumps-into-2-new-biotech-companies | Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Premium feature. | Andreas Halvorsen Jumps Into 2 New Biotech Companies | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2020-12-15 21:03:00 | https://www.businesswire.com/news/home/20201215006193/en/AbCellera-Announces-Closing-of-Initial-Public-Offering-and-Exercise-in-Full-of-the-Underwriters%E2%80%99-Option-to-Purchase-Additional-Shares/ | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2020-12-11 17:58:46 | https://www.fool.com/investing/2020/12/11/ipo-stock-madness-moves-to-biotech-as-abcellera-ce/ | Hot initial public offerings aren't just for technology companies. | IPO Stock Madness Moves to Biotech as AbCellera, Certara Soar | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2020-12-11 12:36:00 | https://www.barrons.com/articles/certara-abcellera-lead-flurry-of-health-care-ipos-51607708207 | Four companies increased the size of their deals. | Certara, AbCellera Lead Flurry of Health-Care IPOs | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2020-12-10 22:47:00 | https://www.businesswire.com/news/home/20201210006243/en/AbCellera-Announces-Pricing-of-Initial-Public-Offering/ | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share. | AbCellera Announces Pricing of Initial Public Offering | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2020-12-07 19:13:20 | https://seekingalpha.com/article/4393483-abcellera-biologics-proposes-357-million-ipo-terms | AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide. | AbCellera Biologics Proposes $357 Million IPO Terms | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-23 15:44:06 | https://www.fool.com/investing/2023/06/23/why-shares-of-abcam-are-jumping-friday/ | Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022. | Why Shares of Abcam Are Jumping Friday | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-21 13:19:08 | https://www.zacks.com/stock/news/2111377/are-you-looking-for-a-top-momentum-pick-why-abcam-plc-sponsored-adr-abcm-is-a-great-choice | Does Abcam PLC Sponsored ADR (ABCM) have what it takes to be a top stock pick for momentum investors? Let's find out. | Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-21 08:48:12 | https://www.zacks.com/stock/news/2111081/3-stocks-with-upgraded-broker-ratings-for-robust-returns | As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We choose Abcam (ABCM), Maxeon Solar (MAXN) and Allegiant Travel (ALGT) as these witness rating upgrades. | 3 Stocks With Upgraded Broker Ratings for Robust Returns | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-20 11:01:39 | https://www.zacks.com/stock/news/2110535/is-abcam-abcm-outperforming-other-medical-stocks-this-year | Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year. | Is Abcam (ABCM) Outperforming Other Medical Stocks This Year? | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-15 12:47:47 | https://www.fool.com/investing/2023/06/15/why-shares-in-abcam-surged-this-week/ | Abcam operates in some highly attractive end markets, but its operational execution is not what it should be, according to its funder and former director. Dr. Jonathan Milner has called for the removal of three board members and his appointment as executive chairman. | Why Shares in Abcam Surged This Week | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-09 09:00:00 | https://seekingalpha.com/article/4610477-abcam-abcm-nosebleed-valuations-flat-growth-profile-justify-hold-rating | Abcam plc's outlook remains unchanged after a mixed FY'22, with improvements needed in fundamental, sentiment, and valuation factors to attract buyers. Despite a strong FY'22, ABCM's poor returns on capital, economic losses and flat growth outlook hinder its investment potential. The company needs to enhance performanc... | Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-23 11:08:22 | https://www.zacks.com/stock/news/2098536/how-much-upside-is-left-in-abcam-plc-sponsored-adr-abcm-wall-street-analysts-think-27-55 | The mean of analysts' price targets for Abcam PLC Sponsored ADR (ABCM) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | How Much Upside is Left in Abcam PLC Sponsored ADR (ABCM)? Wall Street Analysts Think 27.55% | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-03-20 11:52:06 | https://seekingalpha.com/article/4588766-abcam-plc-abcm-q4-2022-earnings-call-transcript | State Bank of India ADR (NASDAQ:ABCM ) Q4 2022 Earnings Conference Call March 20, 2023 8:00 AM ET Company Participants Tommy Thomas - Vice President of Investor Relations Alan Hirzel - Chief Executive Officer Michael Baldock - Chief Financial Officer Conference Call Participants Tejas Sevant - Morgan Stanley Puneet Sou... | Abcam plc (ABCM) Q4 2022 Earnings Call Transcript | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2023-03-10 08:00:00 | https://www.prnewswire.com/news-releases/abcam-to-report-full-year-results-on-monday-march-20-2023-301768357.html | CAMBRIDGE, England and WALTHAM, Mass. , March 10, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m. | Abcam to Report Full Year Results on Monday, March 20, 2023 | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-29 07:30:00 | https://seekingalpha.com/article/4543735-abcam-good-growth-stock-health-market | I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company. | Abcam: A Good Growth Stock In The Healthcare Market | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-12 13:15:03 | https://seekingalpha.com/article/4540435-abcam-plc-abcm-q4-2022-earnings-call-transcript | Abcam plc (NASDAQ:ABCM ) Q4 2022 Results Conference Call September 12, 2022 8:00 AM ET Company Participants Tommy Thomas - IR Alan Hirzel - CEO Michael Baldock - CFO Conference Call Participants Tejas Savant - Morgan Stanley Charles Weston - RBC Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - ... | Abcam plc (ABCM) Q4 2022 Earnings Call Transcript | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-14 12:38:05 | https://seekingalpha.com/article/4495325-abcam-abcm-ceo-alan-hirzel-on-q4-2021-results-earnings-call-transcript | Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript | Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-09-15 17:55:31 | https://www.gurufocus.com/news/1524752/4-high-financial-strength-stocks-trading-near-historical-low-pricebook-ratios | According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, four stocks with high financial strength and are trading near historical low price-book ratios are Landstar System Inc. ( LSTR , Financial), 51job Inc. ( JOBS , Financial), Abcam PLC ( ABCM , Financial) and SAP SE ( SAP , Financial). | 4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Proactive Investors | 2021-08-02 10:37:40 | https://www.proactiveinvestors.co.uk//companies/news/956635/abcam-jumps-as-it-snaps-up-major-supplier-biovision-956635.html?SNAPI | Abcam PLC shares rose on Monday as the research tools maker said it had struck a deal to acquire BioVision Inc, a subsidiary of chemicals firm Chinese firm NKY Medical Holdings, for US$340mln in cash. BioVision distributes research tools and has a strength in the assay kits market, Abcam said, adding that the purchase... | Abcam jumps as it snaps up major supplier BioVision | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-08-02 07:38:36 | https://www.benzinga.com/m-a/21/08/22270560/abcam-to-acquire-supplier-biovision-for-340m-in-cash | Abcam plc (NASDAQ: ABCM) has agreed to acquire BioVision Inc, a wholly-owned Boai NKY Medical Holdings Ltd subsidiary, for $340 million in cash. The Milpitas, California-based BioVision is a distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell... | Abcam To Acquire Supplier BioVision For $340M In Cash | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-08-02 02:00:00 | https://www.globenewswire.com/news-release/2021/08/02/2272548/0/en/Abcam-to-Acquire-BioVision-for-340-million.html | CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly ow... | Abcam to Acquire BioVision for $340 million | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-29 10:39:30 | https://www.zacks.com/stock/news/1770308/new-strong-sell-stocks-for-july-29th | ABCM, CCJ, EBMT, MRTN and NESR have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2021. | New Strong Sell Stocks for July 29th | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Proactive Investors | 2021-07-22 02:28:36 | https://www.proactiveinvestors.com.au//companies/news/955677/proteomics-international-engages-abcam-to-manufacture-promarkerd-reagents-955677.html?SNAPI | Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC) (OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes. Abcam is a leader in the... | Proteomics International engages Abcam to manufacture PromarkerD reagents | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-13 07:00:00 | https://www.prnewswire.com/news-releases/abcam-opens-new-us-facility-in-boston-ma-301332406.html | CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central component of Abcam's growth in the United States, reinforcing its commitment to support the res... | Abcam opens new US facility in Boston, MA | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-09 09:56:20 | https://seekingalpha.com/article/4438458-abcam-plc-promising-business-model-drug-industry | I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers. | Abcam: A Promising Business Model In The Drug Industry | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-22 08:00:00 | https://www.prnewswire.com/news-releases/pionyr-and-abcam-extend-partnership-to-evaluate-trem2-expressing-cells-in-cancer-patients-301317233.html | SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools, anno... | Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-04-12 05:00:00 | https://www.globenewswire.com/news-release/2021/04/12/2207974/0/en/Abcam-and-MEDx-extend-precision-medicine-strategic-partnership.html | CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnost... | Abcam and MEDx extend precision medicine strategic partnership | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-04-06 06:21:00 | https://www.businesswire.com/news/home/20210406005525/en/Avacta-Announces-Distribution-Agreement-With-ABCAM-plc/ | CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the... | Avacta Announces Distribution Agreement With ABCAM plc | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-03-26 17:56:44 | https://www.gurufocus.com/news/1389007/5-companies-trading-below-historical-low-pricebook-as-of-march | Stocks with high business profitability and price-book ratios near 10-year lows | 5 Companies Trading Below Historical Low Price-Book as of March | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-24 07:49:00 | https://www.globenewswire.com/news-release/2021/03/24/2198386/0/en/Abcam-Wins-Industry-Awards-from-CiteAb.html | CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact' and the Company was recognized as ‘Ant... | Abcam Wins Industry Awards from CiteAb | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-08 14:40:43 | https://seekingalpha.com/article/4412311-abcam-abczf-ceo-alan-hirzel-on-2021-interim-results-earnings-call-transcript | Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript | Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-08 07:00:00 | https://www.globenewswire.com/news-release/2021/03/08/2188549/0/en/8-3-constant-currency-revenue-growth-in-H1-as-customers-gradually-return-to-labs.html | CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”). | 8.3% constant currency revenue growth in H1 as customers gradually return to labs | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-03-04 04:00:00 | https://www.globenewswire.com/news-release/2021/03/04/2186812/0/en/Abcam-Expands-Presence-in-China-to-Support-Increased-Demand-of-BioPharma-Sector.html | CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and ma... | Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-26 02:00:00 | https://www.globenewswire.com/news-release/2021/02/26/2183102/0/en/Abcam-to-Report-Interim-Results-on-Monday-March-8-2021.html | CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, ... | Abcam to Report Interim Results on Monday, March 8, 2021 | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-02-17 07:00:00 | https://www.globenewswire.com/news-release/2021/02/17/2176944/0/en/Abcam-to-present-at-the-2021-SVB-Leerink-Global-Healthcare-Conference.html | CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be acc... | Abcam to present at the 2021 SVB Leerink Global Healthcare Conference | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2021-01-28 02:00:00 | https://www.globenewswire.com/news-release/2021/01/28/2165487/0/en/Abcam-Plc-Appointment-of-Non-Executive-Directors.html | CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. | Abcam Plc Appointment of Non-Executive Directors | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-01-18 08:15:32 | https://seekingalpha.com/article/4399476-abcam-attractive-profitable-medtech-pricy | Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well. | Abcam: An Attractive, Profitable Medtech But Pricy | ABCM | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-22 00:15:03 | https://seekingalpha.com/article/4618933-accolade-leveraging-tech-to-deliver-accessible-healthcare | Accolade is experiencing strong demand due to rising healthcare costs and employers seeking ways to reduce expenses. The company's proprietary technology platform and health assistants provide personalized benefits and health support, leading to significant cost savings for customers. Accolade's unique value propositio... | Accolade: Leveraging Tech To Deliver Accessible Healthcare | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-07-20 15:56:18 | https://seekingalpha.com/article/4618527-accolade-growth-reacceleration-in-fy25-should-drive-valuation-upside | I maintain a buy rating for ACCD as I expect growth reacceleration in FY25 which will drive valuation upwards. ACCD's management has raised revenue expectations for FY24 and reiterated long-term revenue targets. Potential risks include rising interest rates and the possibility of management missing profit outlook, whic... | Accolade: Growth Reacceleration In FY25 Should Drive Valuation Upside | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2023-07-11 07:00:14 | https://www.marketbeat.com/originals/accolade-a-rising-personalized-ai-powered-healthcare-platform/?utm_source=snapi | Accolade Inc. NASDAQ: ACCD is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people manage their health by finding the right care and providers. | Accolade: A Rising Personalized AI-Powered Healthcare Platform | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-06-30 18:42:01 | https://www.fool.com/investing/2023/06/30/why-accolade-stock-popped-by-almost-7-today/ | The specialty healthcare solutions provider unveiled its latest set of quarterly results. These handily beat analyst estimates on both the top and bottom lines. | Why Accolade Stock Popped by Almost 7% Today | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-06-29 19:23:04 | https://seekingalpha.com/article/4614503-accolade-inc-accd-q1-2024-earnings-call-transcript | Accolade, Inc. (NASDAQ:ACCD ) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Health Officer Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Jeff Garrow - Stephens, Inc... | Accolade, Inc. (ACCD) Q1 2024 Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-06-29 18:54:39 | https://www.zacks.com/stock/news/2115002/accolade-accd-reports-q1-loss-tops-revenue-estimates | Accolade (ACCD) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.40 per share a year ago. | Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-06-13 08:00:00 | https://www.globenewswire.com/news-release/2023/06/13/2687045/0/en/Accolade-to-Announce-Fiscal-First-Quarter-2024-Financial-Results.html | SEATTLE, June 13, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal first quarter 2024 financial results on Thursday, June 29, 2023, after the market closes. In conjunction, the company will host a conference call t... | Accolade to Announce Fiscal First Quarter 2024 Financial Results | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-06-01 11:04:00 | https://www.globenewswire.com/news-release/2023/06/01/2680585/0/en/Accolade-To-Present-at-Stifel-2023-Cross-Sector-Insight-Conference.html | SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stifel 2023 Cross Sector Insight Conference in Boston on Tuesday, June 6, 2023 at 11:30 am ET. A webcast of the event will be available at ir... | Accolade To Present at Stifel 2023 Cross Sector Insight Conference | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-27 10:24:40 | https://seekingalpha.com/article/4607826-accolade-fy25-and-long-term-target-instils-confidence | ACCD has experienced high demand, with revenue increasing by 5.6% in 4Q23 and a 33% increase in ARR bookings. During the analyst day, ACCD upgraded its FY25 margin target and expressed confidence in reaching $500 million in sales. | Accolade: FY25 And Long-Term Targets Inspire Confidence | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2023-05-25 22:08:38 | https://www.gurufocus.com/news/2008524/accolade-inc-cfo-stephen-barnes-sells-631-shares-an-insider-sell-analysis | On May 23, 2023, Stephen Barnes, the Chief Financial Officer (CFO) of Accolade Inc ( ACCD , Financial), sold 631 shares of the company. This article will provide an overview of Stephen Barnes, Accolade Inc's business, and an analysis of insider buy/sell transactions and their relationship with the stock price. | Accolade Inc CFO Stephen Barnes Sells 631 Shares: An Insider Sell Analysis | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2023-05-25 22:08:34 | https://www.gurufocus.com/news/2008525/accolade-inc-ceo-rajeev-singh-sells-1553-shares-an-insider-sell-analysis | On May 23, 2023, Rajeev Singh, the CEO of Accolade Inc ( ACCD , Financial), sold 1,553 shares of the company. This article will provide an analysis of this insider sell, the relationship between insider transactions and stock price, and an overview of Accolade Inc and its CEO, Rajeev Singh. | Accolade Inc CEO Rajeev Singh Sells 1,553 Shares: An Insider Sell Analysis | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2023-05-25 22:07:31 | https://www.gurufocus.com/news/2008523/accolade-inc-ceo-rajeev-singh-sells-1456-shares | On May 24, 2023, Rajeev Singh, the CEO of Accolade Inc ( ACCD , Financial), sold 1,456 shares of the company's stock. This move comes amidst a year of both buying and selling activity for Singh, who has sold a total of 10,100 shares and purchased 35,000 shares over the past year. | Accolade Inc CEO Rajeev Singh Sells 1,456 Shares | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-24 13:13:21 | https://www.zacks.com/stock/news/2099215/accolade-accd-upgraded-to-buy-what-does-it-mean-for-the-stock | Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Accolade (ACCD) Upgraded to Buy: What Does It Mean for the Stock? | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2023-05-11 08:00:00 | https://www.benzinga.com/trading-ideas/long-ideas/23/05/32337889/top-5-health-care-stocks-that-could-lead-to-your-biggest-gains-in-may?SNAPI | The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. | Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD) | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-27 23:11:05 | https://seekingalpha.com/article/4597610-accolade-inc-accd-q4-2023-earnings-call-transcript | Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript. | Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-04-27 19:01:15 | https://www.zacks.com/stock/news/2086407/accolade-accd-reports-q4-loss-misses-revenue-estimates | Accolade (ACCD) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.27 per share a year ago. | Accolade (ACCD) Reports Q4 Loss, Misses Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-04-24 16:05:00 | https://www.globenewswire.com/news-release/2023/04/24/2653316/0/en/Accolade-to-Webcast-Analyst-Day-on-May-8-2023.html | SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will host an Analyst Day at the Wynn Las Vegas on May 8, 2023 and will provide a webcast of the event beginning at 1pm PT. | Accolade to Webcast Analyst Day on May 8, 2023 | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2023-04-11 08:00:00 | https://www.globenewswire.com/news-release/2023/04/11/2644316/0/en/Accolade-to-Announce-Fiscal-Fourth-Quarter-2023-Financial-Results.html | SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal fourth quarter 2023 financial results on Thursday, April 27, 2023, after the market closes. In conjunction, the company will host a conference cal... | Accolade to Announce Fiscal Fourth Quarter 2023 Financial Results | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GeekWire | 2023-03-06 20:32:33 | https://www.geekwire.com/2023/healthcare-company-accolade-lays-off-workers-and-closes-offices/ | Seattle and Philadelphia area-based primary healthcare company Accolade is cutting its workforce and closing or reducing some facilities, according to a recent regulatory filing. | Healthcare company Accolade lays off workers and closes offices | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2023-01-13 12:39:09 | https://www.fool.com/investing/2023/01/13/why-shares-of-accolade-soared-this-week/ | Strong revenue growth and encouraging guidance pushed the stock up. | Why Shares of Accolade Soared This Week | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-01-09 21:58:02 | https://seekingalpha.com/article/4568878-accolade-inc-accd-q3-2023-earnings-call-transcript | Accolade, Inc. (NASDAQ:ACCD ) Q3 2023 Earnings Conference Call January 9, 2023 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael ... | Accolade, Inc. (ACCD) Q3 2023 Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-01-09 18:48:23 | https://www.zacks.com/stock/news/2036970/accolade-accd-reports-q3-loss-tops-revenue-estimates | Accolade (ACCD) delivered earnings and revenue surprises of 8.20% and 4.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock? | Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-12-20 08:00:00 | https://www.globenewswire.com/news-release/2022/12/20/2577010/0/en/Accolade-to-Announce-Fiscal-Third-Quarter-2023-Financial-Results.html | SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company will host a conference call t... | Accolade to Announce Fiscal Third Quarter 2023 Financial Results | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-06 22:39:03 | https://seekingalpha.com/article/4545172-accolade-inc-accd-q2-2023-results-earnings-call-transcript | Accolade Inc. (NASDAQ:ACCD ) Q2 2023 Earnings Conference Call October 6, 2022 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael C... | Accolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-06 18:48:23 | https://www.zacks.com/stock/news/1988900/accolade-accd-reports-q2-loss-tops-revenue-estimates | Accolade (ACCD) delivered earnings and revenue surprises of 7.04% and 5.68%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock? | Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-09-29 11:17:15 | https://www.zacks.com/stock/news/1986548/accolade-accd-expected-to-beat-earnings-estimates-should-you-buy | Accolade (ACCD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Accolade (ACCD) Expected to Beat Earnings Estimates: Should You Buy? | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-07-01 12:51:01 | https://www.benzinga.com/news/22/07/27934481/heres-why-accolade-shares-are-trading-higher-today | Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for. | Here's Why Accolade Shares Are Trading Higher Today | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-07-01 09:08:00 | https://www.marketbeat.com/originals/accolade-moves-higher-but-growth-is-slowing/?SNAPI | Accolade (NASDAQ: ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company's business and has on track to continue growing but there is a fly in the ointment... | Accolade Moves Higher But Growth Is Slowing | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-30 23:18:02 | https://seekingalpha.com/article/4521294-accolade-inc-accd-ceo-rajeev-singh-on-q1-2023-results-earnings-call-transcript | Accolade, Inc. (NASDAQ:ACCD ) Q1 2023 Earnings Conference Call June 30, 2022 4:30 PM ET Company Representatives Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior Vice President of Investor Relations Conference Call Participants Ry... | Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2023 Results - Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-30 18:46:05 | https://www.zacks.com/stock/news/1946453/accolade-accd-reports-q1-loss-tops-revenue-estimates | Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock? | Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-27 15:22:14 | https://www.zacks.com/stock/news/1944618/accolade-accd-stock-jumps-7-2-will-it-continue-to-soar | Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. | Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar? | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-06-02 13:02:00 | https://www.globenewswire.com/news-release/2022/06/02/2455511/0/en/Accolade-Announces-Participation-in-June-Investor-Conferences.html | SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com. | Accolade Announces Participation in June Investor Conferences | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-05-09 13:00:00 | https://www.globenewswire.com/news-release/2022/05/09/2438937/0/en/Accolade-Announces-Participation-in-May-Investor-Conferences.html | SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com. | Accolade Announces Participation in May Investor Conferences | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-02 15:41:46 | https://investorplace.com/2022/05/why-is-accolade-accd-stock-up-today/ | Today, investors in Accolade and ACCD stock have something to cheer, following a rather dismal end to last week. The post Why Is Accolade (ACCD) Stock Up Today? | Why Is Accolade (ACCD) Stock Up Today? | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2022-05-02 12:14:00 | https://www.barrons.com/articles/accolade-accd-stock-upgrade-51651507998 | Wells Fargo upgrades Accolade to Equal Weight from Underweight, saying the stock's current price point creates a more balanced risk-and-reward profile. | Accolade Stock Rebounds. It's Upgraded on More Balanced Risk-Reward. | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-04-29 14:10:13 | https://www.benzinga.com/news/earnings/22/04/26901455/why-are-accolade-shares-down-50-today | Accolade Inc (NASDAQ: ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. | Why Are Accolade Shares Down Over 40% Today | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-04-29 13:13:00 | https://www.marketwatch.com/story/accolade-stock-suffers-record-plunge-after-earnings-miss-loss-of-largest-customer-11651252401 | Shares of Accolade Inc. lost nearly half their value Friday, after the personalized virtual health care services company reported a wider-than-expected fiscal fourth-quarter loss, and said it would lose its largest customer at the end of the year. | Accolade stock suffers record plunge after earnings miss, loss of largest customer | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-29 00:09:09 | https://seekingalpha.com/article/4504922-accolade-inc-accd-ceo-rajeev-singh-on-q4-2022-results-earnings-call-transcript | Accolade, Inc. (NASDAQ:ACCD ) Q4 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair Jonathan Young - C... | Accolade, Inc. (ACCD) CEO Rajeev Singh on Q4 2022 Results - Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-28 20:18:11 | https://www.zacks.com/stock/news/1910934/accolade-accd-reports-q4-loss-tops-revenue-estimates | Accolade (ACCD) delivered earnings and revenue surprises of -17.39% and 1.82%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock? | Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-04-14 08:00:00 | https://www.globenewswire.com/news-release/2022/04/14/2422676/0/en/Accolade-to-Announce-Fiscal-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html | SEATTLE, April 14, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal fourth quarter and full year 2022 financial results on Thursday, April 28, 2022, after the market closes. In conjunction, t... | Accolade to Announce Fiscal Fourth Quarter and Full Year 2022 Financial Results | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GlobeNewsWire | 2022-02-16 08:00:00 | https://www.globenewswire.com/news-release/2022/02/16/2386154/0/en/Accolade-to-Participate-in-the-2022-SVB-Leerink-Global-Healthcare-Conference.html | SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Global Healthcare Conference, including a fireside chat presentation on Friday, February 18, 2022 at 2:20 p.m. E.T. A webcast w... | Accolade to Participate in the 2022 SVB Leerink Global Healthcare Conference | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2022-01-11 11:54:05 | https://pulse2.com/accolade-stock-nasdaq-accd-why-the-price-surged-today/ | The stock price of Accolade Inc (NASDAQ: ACCD) increased by over 20% during intraday trading today. This is why it happened. | Accolade Stock (ACCD): Why The Price Surged Today | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-01-11 06:07:45 | https://www.benzinga.com/news/earnings/22/01/24989555/accolade-shares-trade-higher-after-117-jump-in-q3-sales | Accolade Inc (NASDAQ: ACCD) reported Q3 FY22 sales of $83.5 million, up 117% Y/Y, beating the consensus of $75.89 million. The adjusted EBITDA loss widened to $(11.9) million, and the adjusted gross margin improved from 41.8% to 47%. | Accolade Shares Trade Higher After 117% Jump In Q3 Sales | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-11 00:22:04 | https://seekingalpha.com/article/4478917-accolade-inc-s-accd-ceo-rajeev-singh-on-q3-2022-results-earnings-call-transcript | Accolade, Inc.'s (ACCD) CEO Rajeev Singh on Q3 2022 Results - Earnings Call Transcript | Accolade, Inc.'s (ACCD) CEO Rajeev Singh on Q3 2022 Results - Earnings Call Transcript | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-10 19:09:41 | https://www.zacks.com/stock/news/1849881/accolade-accd-reports-q3-loss-tops-revenue-estimates | Accolade (ACCD) delivered earnings and revenue surprises of 18.75% and 9.85%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock? | Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates | ACCD | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.